Table 1 Patient demographics.
Variable | Overall | Allogeneic | Autologous |
|---|---|---|---|
(n = 453) | (n = 366) | (n = 87) | |
Patient age at diagnosis (years), median (IQR 25–75) | 40.6 (29.5–50.7) | 41.2 (30.5–51.1) | 37.6 (28.9–48.6) |
Patient age at transplant (years), median (IQR 25–75) | 43.3 (31.8–53.1) | 44.1 (32.3–53.3) | 39.3 (31.3–50.5) |
Patient Age at follow up (years), median (IQR 25–75) | 52.1 (40.7–60.6) | 52.0 (40.5–60.5) | 52.5 (41.6–61.3) |
Survival (years), median (IQR 25–75) | 6.14 (3.27–10.6) | 5.7 (3.2–9.6) | 9.7 (4.5–16.9) |
Gender, n (%) | |||
Male | 258 (57.0) | 212 (57.9) | 46 (52.9) |
Female | 195 (43.0) | 154 (42.1) | 41 (47.1) |
Diagnosis, n (%) | |||
Acute leukaemia | 172 (38.0) | 162 (44.3) | 10 (11.5) |
Chronic leukaemia | 57 (12.6) | 57 (15.6) | 0 (0.0) |
Lymphoma | 125 (27.6) | 51 (13.9) | 74 (85.1) |
Plasma cell disorders | 22 (4.9) | 20 (5.5) | 2 (2.3) |
Solid tumours | 1 (0.2) | 0 (0.0) | 1 (1.2) |
Myelodysplastic/Myeloproliferative | 58 (12.8) | 58 (15.8) | 0 (0.0) |
Bone marrow failure | 17 (3.8) | 17 (4.6) | 0 (0.0) |
Inherited disorders | 1 (0.2) | 1 (0.3) | 0 (0.0) |
Ethnicity, n (%) | |||
European Caucasian | 444 (98.7) | 358 (98.6) | 86 (98.9) |
South and South-East Asian | 4 (0.9) | 3 (0.8) | 1 (1.1) |
Ethnic South and Central American origins | 1 (0.2) | 1 (0.3) | 0 (0.0) |
African Caribbean | 1 (0.2) | 1 (0.3) | 0 (0.0) |
Missing | 3 | 3 | 0 |
ECOG at time of evaluation, n (%) | |||
0 | 333 (76.2) | 267 (76.1) | 66 (76.7) |
1 | 90 (20.6) | 74 (21.1) | 16 (18.6) |
2 | 11 (2.5) | 8 (2.3) | 3 (3.5) |
3 | 2 (0.5) | 1 (0.3) | 1 (1.2) |
4 | 1 (0.2) | 1 (0.3) | 0 (0.0) |
Missing | 16 | 15 | 1 |
Conditioning type (allo only), n (%) | |||
MAC | 158 (47.6) | ||
RIC-Chemo | 150 (45.2) | ||
RIC-TBI | 24 (7.2) | ||
Missing | 36 | ||
Second malignancy (any kind), n (%) | |||
No | 392 (89.7) | 316 (89.0) | 76 (92.7) |
Yes | 45 (10.3) | 39 (11.0) | 6 (7.3) |
Missing | 16 | 11 | 5 |
